Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Reports Positive Early Results from Phase I Trial of ROR1 ADC

publication date: May 24, 2024

Suzhou CStone Pharma released positive data from its global first-in-human Phase 1a/1b study of a ROR1 candidate in patients with advanced solid tumors and lymphomas. CStone says CS5001 is a key asset in its Pipeline 2.0. The novel ROR1-targeted ADC is designed with a unique pyrrolobenzodiazepine (PBD) prodrug. CStone believes the combination of the PBD prodrug and its linker minimizes the toxicity of traditional PBD payloads. In a dose ascending trial, CS5001 has completed the first eight dose levels (7 to 125 μg/kg) without reaching the maximum tolerated dose. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital